Literature DB >> 34019284

Methods of Expression, Purification, and Preparation of the c-Myc b-HLH-LZ for Its Biophysical Characterization.

Patrick Delattre1, Martin Montagne1, Pierre Lavigne2.   

Abstract

The b-HLH-LZ domain of c-Myc is a key target for the development of cancer therapies by blunting its binding to DNA with cell penetrant b-HLH-LZs and/or by stabilizing it into a state that cannot recognize Max to activate and amplify transcription of oncogenic genes. Although recent milestones have been reached with DNA binding blunting of c-Myc with the cell penetrant b-HLH-LZ Omomyc, the targeting of its b-HLH-LZ with small molecules, peptides, or proteins is lagging. As reviewed recently, the main problem relies in the intrinsically disordered nature of the b-HLH-LZ of c-Myc. This greatly complicates the classical approach of targeting a docking site with inhibitors. The solution state methods such as NMR are progressing towards the characterization of the ensembles of structures or states the b-HLH-LZ can adopt. However, the delicate balance that dictates the population of these dynamically interchanging states relies on its primary structure and the weak polar, electrostatic and hydrophobic interactions allowed. In this context, it is of the utmost importance to study the b-HLH-LZ of c-Myc in its WT background and avoid the use of tags such as His-tags. These tags could disrupt the balance of forces which could alter the conformational and physical transitions and states it can undergo and adopt. Here, we describe a robust protocol to express the WT b-HLH-LZ in E. coli and purify it, without the need of tags, to obtain the required quantities for solution state biophysical characterization such as NMR.

Entities:  

Keywords:  NMR; Protein expression and purification; b-HLH-LZ; c-Myc

Year:  2021        PMID: 34019284     DOI: 10.1007/978-1-0716-1476-1_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

Authors:  Yu-Ting Chou; Hua-Heng Lin; Yung-Chang Lien; Yuan-Hung Wang; Chun-Fu Hong; Yu-Rung Kao; Sheng-Chieh Lin; Ying-Che Chang; Shu-Yu Lin; Shu-Jen Chen; Hua-Chien Chen; Shauh-Der Yeh; Cheng-Wen Wu
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

2.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Authors:  Catherine M Shachaf; Andrew J Gentles; Sailaja Elchuri; Debashis Sahoo; Yoav Soen; Orr Sharpe; Omar D Perez; Maria Chang; Dennis Mitchel; William H Robinson; David Dill; Garry P Nolan; Sylvia K Plevritis; Dean W Felsher
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 3.  MYC leads the way.

Authors:  Niranjan Venkateswaran; Maralice Conacci-Sorrell
Journal:  Small GTPases       Date:  2017-11-25

4.  MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.

Authors:  Yulin Li; Peter S Choi; Stephanie C Casey; David L Dill; Dean W Felsher
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

5.  Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.

Authors:  Marie-Eve Beaulieu; Toni Jauset; Daniel Massó-Vallés; Sandra Martínez-Martín; Peter Rahl; Loïka Maltais; Mariano F Zacarias-Fluck; Sílvia Casacuberta-Serra; Erika Serrano Del Pozo; Christopher Fiore; Laia Foradada; Virginia Castillo Cano; Meritxell Sánchez-Hervás; Matthew Guenther; Eduardo Romero Sanz; Marta Oteo; Cynthia Tremblay; Génesis Martín; Danny Letourneau; Martin Montagne; Miguel Ángel Morcillo Alonso; Jonathan R Whitfield; Pierre Lavigne; Laura Soucek
Journal:  Sci Transl Med       Date:  2019-03-20       Impact factor: 17.956

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.